bullish

Oscotec Inc

Oscotec (039200 KQ) - Birth of a Proud K-Blockbuster

250 Views23 Aug 2024 19:05
Broker
The FDA approved the lazertinib+amivantamab therapy on Aug 20.  A monumental case for a local anti-cancer drug to get FDA approval for commercial use in the US
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 9-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Daishin Securities
External broker reports(aggregated public sources)
Daishin Securities
South KoreaEquity Bottom-Up
Price Chart(Sign Up to Access)
analytics-chart
  • Oscotec (039200 KQ) - Birth of a Proud K-Blockbuster
    23 Aug 2024
x